Neurology
Latest news
579 articles · 20 / page
Drug-Coated Balloons Superior to Bare-Metal Stents in Preventing Restenosis for High-Grade Intracranial Atherosclerosis
A multicenter randomized controlled trial demonstrates that drug-coated balloons significantly reduce 6-month restenosis and 1-year recurrent ischemic events compared to bare-metal stents in patients with symptomatic high-grade intracranial
Drug-Coated Balloons Outperform Bare-Metal Stents in Reducing Restenosis for Symptomatic Intracranial Stenosis
A multicenter RCT demonstrates that drug-coated balloon (DCB) angioplasty significantly reduces 6-month restenosis and 1-year recurrent ischemic events compared to bare-metal stenting in patients with high-grade symptomatic intracranial ath
Edaravone Dexborneol Improves Functional Recovery Following Endovascular Thrombectomy: Primary Results from the TASTE-2 Trial
The multicenter TASTE-2 trial reveals that edaravone dexborneol significantly increases the likelihood of functional independence at 90 days for acute ischaemic stroke patients undergoing thrombectomy, particularly those presenting with a c
Targeting the Right Brain: Structural Subtyping and Vascular Profiles Predict Response to Lifestyle Interventions in Dementia Prevention
A sub-analysis of the FINGER trial reveals that individuals with specific grey matter patterns and lower vascular risk derive the most structural brain benefit from multimodal lifestyle interventions, highlighting the potential for personal
Long-Term Gains vs. Short-Term Risks: Decoding the Role of Bailout Angioplasty in Acute Large Vessel Occlusion
The ANGEL-REBOOT trial reveals that while bailout angioplasty (BAOS) increases short-term procedural risks, it significantly improves one-year functional outcomes and reduces stroke recurrence in patients with failed thrombectomy or high-gr
Routine Cerebral Embolic Protection Fails to Mitigate Stroke or Cognitive Decline in TAVI: Results from the BHF PROTECT-TAVI Trial
The landmark BHF PROTECT-TAVI trial reveals that cerebral embolic protection (CEP) does not reduce periprocedural stroke or cognitive impairment following TAVI. This large-scale study challenges the routine use of embolic filters, suggestin
Vanishing Act: Novel Biodegradable PFO Closure Device Matches Nitinol Efficacy in Landmark Randomized Trial
A multicenter randomized trial confirms that a novel biodegradable PFO closure device is noninferior to nitinol devices, achieving high closure rates and disappearing from echocardiography within two years, potentially reducing long-term fo
Pushing the Limits: Very Low LDL-C Levels Below 40 mg/dL Proven Safe and Effective for Secondary Stroke Prevention
A long-term analysis of the FOURIER trials reveals that achieving ultra-low LDL-C levels (
Beyond the Futility Threshold: Deferoxamine May Accelerate Recovery and Benefit Specific Subgroups in Intracerebral Hemorrhage
While the primary i-DEF trial results suggested futility for deferoxamine in unselected intracerebral hemorrhage patients, recent post hoc analyses reveal significant benefits in early neurological improvement, long-term recovery trajectori
Decompressive Craniectomy Benefits Persist Across Deep Intracerebral Hemorrhage Locations: A SWITCH Trial Analysis
A post hoc analysis of the SWITCH trial demonstrates that the clinical benefits of decompressive craniectomy in reducing death and severe disability are consistent across different anatomical locations of deep supratentorial intracerebral h
Novel MicroNet-Covered Stent Sets New Safety Standard for High-Risk Carotid Artery Stenting: Insights from the C-GUARDIANS Trial
The C-GUARDIANS trial reveals that the CGuard MicroNet-covered stent significantly reduces embolic risks in high-risk carotid artery stenting, achieving a remarkably low 30-day DSMI rate of 0.95% and sustained neuroprotection through one ye
Graded Sensorimotor Retraining for Chronic Low Back Pain: Clinical Efficacy and the Search for Treatment Responders
The RESOLVE trial demonstrates that graded sensorimotor retraining provides modest pain relief for chronic low back pain. A secondary analysis reveals that these benefits are consistent across most patient subgroups, suggesting that the int
Fremanezumab Marks a New Era in Pediatric Migraine Prophylaxis: Insights from Phase 3 Trial
A pivotal Phase 3 study published in NEJM demonstrates that Fremanezumab significantly reduces monthly migraine days in children and adolescents, offering a targeted, evidence-based preventive option for a population with high unmet medical
Reevaluating the Efficacy of Music Interventions in Dementia-Related Depression: Critical Insights from the MIDDEL Multinational Trial
Highlights Background Dementia and depression are intertwined public health crises, together accounting for a substantial...
Rethinking First-Line Anticoagulation in Older Adults: Real-World Evidence Challenges Conventional AFib Management
A large-scale study of 144,969 Medicare beneficiaries reveals that initial anticoagulant prescriptions for atrial fibrillation may not reduce ischemic stroke risk in patients over 66, while significantly increasing major bleeding hazards, s
Post-TIA Depression: A Silent Predictor of Mortality and Long-Term Disability Independent of Brain Ischemia
A population-based study reveals that nearly one-quarter of TIA patients experience depression, which significantly increases the risk of mortality and disability, regardless of whether acute ischemic lesions are present on imaging.
Active Cancer Increases Both Ischemic and Bleeding Risks in Minor Stroke Patients on DAPT: Lessons from the READAPT Study
A secondary analysis of the READAPT study reveals that patients with active cancer or hematological malignancies face significantly higher risks of recurrent stroke and bleeding while on dual antiplatelet therapy (DAPT) compared to those in
The 42-Hour Window: Why Delaying Dual Antiplatelet Therapy Compromises Outcomes in Minor Stroke and High-Risk TIA
A large-scale cohort study demonstrates that the efficacy of dual antiplatelet therapy for minor stroke and TIA is highly time-dependent, with maximal benefits seen within 24 hours and a loss of therapeutic effect after approximately 42 hou
Oligodendrocyte Myelin Glycoprotein: A Novel Plasma Determinant of Neurodegenerative Resiliency
A comprehensive multi-cohort proteomic study identifies Oligodendrocyte Myelin Glycoprotein (OMG) as a causal biomarker for neurodegenerative resiliency, linking its peripheral abundance to axonal integrity and reduced risk of dementia and
GLP-1 Receptor Agonists Associated with Significantly Lower Risk of Subarachnoid Hemorrhage in Patients with Intracranial Aneurysms
A large-scale retrospective cohort study reveals that GLP-1 receptor agonists reduce the risk of subarachnoid hemorrhage by 34% and all-cause mortality by 37% in patients with type 2 diabetes and intracranial aneurysms, suggesting a potent
Browse by specialty
Open language-specific specialty feeds and department pages.